Sharafian Samin, Amirzargar Aliakbar, Gharagozlou Mohammad, Parvaneh Nima, Shariat Mansoureh, Tavakol Marzieh, Movahedi Masoud
Department of Immunology and Allergy, Mofid's Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran AND Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Allergy Asthma Immunol. 2022 Jun 18;21(3):232-240. doi: 10.18502/ijaai.v21i3.9797.
Oral immunotherapy (OIT) is a novel approach to desensitization and tolerance induction in food allergy patients. This study aimed to design and implement a new wheat OIT protocol, evaluate its efficacy in tolerance induction, and assess specific immunoglobulin-E (IgE) and regulatory T cell changes. From 2015 to 2017, 26 patients with confirmed IgE-mediated hypersensitivity to wheat were treated via oral immunotherapy (OIT). Patients with prior anaphylactic episodes underwent OIT using the rush method. Specific IgE concentrations and the number of regulatory T cells (CD4+ CD25+ FOXP3+ T cells) were measured using Allergy Screen immunoblot assay and flow cytometry, respectively. This study was registered in the Iranian Registry of Clinical Trials (IRCT20181220042066N1). The results revealed success rates of 100% and 93.3% for desensitization and tolerance. Specific IgE was significantly reduced after 12 months of OIT. No significant change in regulatory T cell numbers was observed. In view of the promising findings of this study, the proposed OIT protocol could be viewed as an effective and valuable method to induce tolerance and desensitization in wheat allergic patients.
口服免疫疗法（OIT）是一种用于食物过敏患者脱敏和诱导耐受的新方法。本研究旨在设计并实施一种新的小麦OIT方案，评估其诱导耐受的疗效，并评估特异性免疫球蛋白E（IgE）和调节性T细胞的变化。2015年至2017年，26例确诊为IgE介导的小麦超敏反应患者接受了口服免疫疗法（OIT）治疗。有过过敏反应发作史的患者采用快速法进行OIT。分别使用Allergy Screen免疫印迹法和流式细胞术测量特异性IgE浓度和调节性T细胞（CD4+ CD25+ FOXP3+ T细胞）数量。本研究已在伊朗临床试验注册中心（IRCT20181220042066N1）注册。结果显示脱敏和耐受的成功率分别为100%和93.3%。OIT治疗12个月后特异性IgE显著降低。调节性T细胞数量未观察到显著变化。鉴于本研究的有前景的发现，所提出的OIT方案可被视为诱导小麦过敏患者耐受和脱敏的一种有效且有价值的方法。
